T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study
Transplant International · 2025
DOI: 10.3389/ti.2025.14443 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplant International, 2025. Verfasst von Simon Aberger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation, Immunosuppressive Agents, HLA-DR Antigens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kidney transplantation (KT) is the current treatment of choice in patients with end-stage kidney disease. Immunosuppression is required to prevent acute rejection but is associated with a high incidence of adverse events. The immunosuppressive burden substantially differs between individuals, necessitating new immune monitoring strategies to achieve personalization of immunosuppression. To compare the evolution of T cell profiles in correlation with immunosuppression and clinical outcomes, 87 kidney transplant recipients were followed for 12 months after KT. Flow cytometry along with assessment of T cell activation markers and clinical data was performed before KT and during study visits 10 days, 2 months and 12 months after KT. Longitudinal T cell phenotyping revealed a significant decrease of T cell activation markers HLA-DR, FCRL3, and CD147 in CD4 + effector T cells after KT. The most pronounced reduction (75%) was found for the activation-proliferation marker HLA-DR, which persisted throughout the observational period. The decrease in HLA-DR expression reflected immunosuppressive burden through strong associations with tacrolimus trough-level exposure (coeff = −0.39, p < 0.01) and BK viremia incidence (coeff = −0.40, p < 0.01) in multivariable regression analysis. T cell activation marker HLA-DR emerges as a potential biomarker for tacrolimus-related immunosuppressive burden in association with BK viremia risk following KT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- Department of Internal Medicine I, Nephrology, Paracelsus Medical University, Salzburg, Austria.
- Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria.
- Center for Biomarker Research in Medicine, Graz, Austria.
- Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Zitieren
APA
Aberger, S., Schuller, M., Mooslechner, A. A., Klötzer, K. A., Prietl, B., Pfeifer, V., Kirsch, A. H., Rosenkranz, A. R., Artinger, K., & Eller, K. (2025). T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study. Transplant International. https://doi.org/10.3389/ti.2025.14443
Vancouver
Aberger S, Schuller M, Mooslechner AA, Klötzer KA, Prietl B, Pfeifer V, et al. T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study. Transplant International. 2025. doi:10.3389/ti.2025.14443
BibTeX
@article{Aberger2025,
author = {Aberger, Simon and Schuller, Max and Mooslechner, Agnes A and Klötzer, Konstantin A and Prietl, Barbara and Pfeifer, Verena and Kirsch, Alexander H and Rosenkranz, Alexander R and Artinger, Katharina and Eller, Kathrin},
title = {T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study},
journal = {Transplant International},
year = {2025},
doi = {10.3389/ti.2025.14443}
}
EUVIMED